Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Lecia V. Sequist, MD
|
|
Give Review
Lecia Sequist practices Oncology. She studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. She received 1 awards: "Regional Top Doctor". Doctor Lecia V. Sequist, MD is a published doctor. She has 89 papers published. The most current publication "Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification." She accepts Medicare.
Publications
- Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
- Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
- Rapid Onset of Retinal Toxicity from High-Dose Hydroxychloroquine Given for Cancer Therapy.
- Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells.
- Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
- Lipodermatosclerosis Secondary to pemetrexed use.
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive Lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two ran...
- Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung Cancer treated with radiotherapy for br...
- Lung Cancer screening, version 1.2015: featured updates to the NCCN guidelines.
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in ...
- Brain tumor cells in circulation are enriched for mesenchymal gene expression.
- Patient-derived models of acquired resistance can identify effective drug combinations for Cancer.
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
- Genotyping Lung Cancer Is an Investment in the Future.
- Acquired resistance to TKIs in solid tumours: learning from lung Cancer.
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- Circulating tumour cells-monitoring treatment response in prostate Cancer.
- Isolation and Molecular Characterization of Circulating Melanoma Cells.
- Reply to F. de Marinis et al.
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.
- Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
- EGFR activating mutations correlate with a Fanconi Anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers.
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Treatment of stage IV non-small cell lung Cancer: Diagnosis and management of lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practic...
- Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
- Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues.
- Circulating Breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
- Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung Cancer.
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung.
- ROS1-Targeted Therapy in Non-Small Cell Lung Cancer.
- Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer.
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer.
- Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations.
- RNA sequencing of Pancreatic circulating tumour cells implicates WNT signalling in metastasis.
- Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung Cancer.
- Genetic changes in squamous cell lung Cancer: a review.
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
- Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung Cancer.
- BIM expression in treatment-naive Cancers predicts responsiveness to kinase inhibitors.
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer.
- A New BATTLE in the Evolving War on Cancer.
- Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC.
- Genotypic and histological evolution of lung Cancers acquiring resistance to EGFR inhibitors.
- Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung Cancer.
- Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung Cancer.
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung Cancer.
- Cetuximab monotherapy in patients with advanced non-small cell lung Cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung Cancer.
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
- Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung Cancer.
- Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung Cancer.
- Exciting new targets in lung Cancer therapy: ALK, IGF-1R, HDAC, and Hh.
- Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate Cancer.
- First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
- Protein degradation/chaperone System and histone deacetylase pathway.
- Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cel...
- Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung Cancer.
- Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung Cancer patients: results of an online tu...
- Toward noninvasive genomic screening of lung Cancer patients.
- The CTC-chip: an exciting new tool to detect circulating tumor cells in lung Cancer patients.
- Effects of erlotinib in EGFR mutated non-small cell lung Cancers with resistance to gefitinib.
- Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung Cancer following cisplatin exposure: a cell culture model of second-line e...
- A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung Cancer.
- Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the Lung.
- Detection of mutations in EGFR in circulating lung-Cancer cells.
- First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung Cancer patients.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- First-line gefitinib in patients with advanced non-small-cell lung Cancer harboring somatic EGFR mutations.
- EGFR tyrosine kinase inhibitors in lung Cancer: an evolving story.
- Non-small cell lung Cancer in octogenarians: treatment practices and preferences.
- Novel agents in the treatment of lung Cancer: Fourth Cambridge Conference.
- Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in Lung adenocarcinomas with bronchioloalveolar features.
- Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung Cancer.
- Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung Cancer.
- Response to treatment and survival of patients with non-small cell lung Cancer undergoing somatic EGFR mutation testing.
- Update on epidermal growth factor receptor inhibitor development in lung Cancer.
- Epidermal growth factor receptor mutation testing in the care of lung Cancer patients.
- Summary statement: novel agents in the treatment of lung Cancer: advances in epidermal growth factor receptor-targeted agents.
- Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung Cancer patients treated with gefitinib or ...
- Autologous and allogeneic stem cell transplantations for poor-risk Chronic lymphocytic leukemia.
- Epidermal growth factor receptor mutations in non-small cell lung Cancer: predicting clinical response to kinase inhibitors.
- Treatment of advanced non-small cell lung Cancer in the elderly.
- Aggressive treatment for the fit elderly with non-small-cell lung Cancer? Yes!
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung Cancer.
- Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
Schools
Harvard Medical School
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1417948316 | |
| NPPES Provider LastName | SEQUIST | |
| NPPES Provider FirstName | LECIA | |
| NPPES Provider ZIPCode | 02114 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 108.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417948316 |
| Last Name Of The Provider | SEQUIST |
| First Name Of The Provider | LECIA |
| View All |
Similar Doctors
|
|
Dr. Kerry E. Kilbridge, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela J. Higgins, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kathy J. Selvaggi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joyce F. Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David E. Fisher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noopur S. Raje, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth H. Stover, MD
This Doctor is OpenDoctor Recommended.
|